It names the pharmacy
A line under the price reads that the product is compounded by a named pharmacy, alongside statements that the physicians are licensed and the records HIPAA-secure. Thirty-two of the one hundred and fifty-eight sellers here name a compounding pharmacy at all.
The Terms go further than most in the other direction too, stating that the platform company does not practise medicine and maintains no financial relationship with the prescribing physicians that would influence a prescription. That is a specific disclaimer rather than a general one, and it is the kind of sentence a reader can hold against later conduct.
Intro pricing, and nothing after it
Both treatment pages price a one-month option and a three-month total, and both are labelled Intro Pricing in the seller's own words. The one-month figures are described as billed monthly at a named starting strength.
We have stored the one-month figures as price rows and the semaglutide one additionally as an introductory rate, and we have derived the per-month equivalents of the three-month totals, showing the division in each qualifier so nobody mistakes a derived figure for a published one.
What is missing is the renewal. Twenty-three of the one hundred and fifty-eight sellers here publish an introductory rate; the good ones print the standing rate beside it. This one does not, and a reader deciding between sellers on the strength of these figures is comparing a first month against somebody else's ongoing bill.
Forty-seven states, counted but not listed
Both pages state a numbered state footprint and link a state-availability page from the footer. A count is better than nothing and it is not a list; we have recorded no state array, because the pages read do not name the states. One hundred and fifteen of the one hundred and fifty-eight sellers here publish no service area at all.
A vial-strength selector sits beside the price on each page, offering several strengths. What the introductory figure buys at the higher strengths is not established, which is the other reason the number is narrower than it looks.
No individual prescribing clinician is named, though a medical-team page is linked from the footer.
TeleClinic's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $79/mothe seller labels this Intro Pricing in its own words, billed monthly at 1 mg to start; the renewal rate is not published on the page | September 2026source |
| Semaglutide (compounded) | $59.67/moper month derived from the seller’s own published Intro Pricing total of $179 for the first three months ($179 divided by 3 is $59.67); the seller prints the total, not this per-month figure, and does not publish what the fourth month costs | September 2026source |
| Tirzepatide (compounded) | $149/mothe seller labels this Intro Pricing in its own words, billed monthly at 5 mg to start; the renewal rate is not published on the page | September 2026source |
| Tirzepatide (compounded) | $133/moper month derived from the seller’s own published Intro Pricing total of $399 for the first three months ($399 divided by 3 is $133); the seller prints the total, not this per-month figure | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See TeleClinic's current price →Good fit if
- Readers who want the compounding pharmacy named on the same line as the price.
- Buyers who want a seller to admit, in its own words, that its published figure is introductory.
- People who want a starting strength printed beside a price rather than a bare monthly number.
Look elsewhere if
- Anyone who needs to know what month four costs. No renewal rate is published anywhere on the priced pages.
- Readers who want a named list of states rather than a count.
- Buyers at a higher strength, since what the intro figure buys above the starting dose is not stated.
- People who want an individual prescribing clinician named.
How this review was verified
- Re-read both treatment pages on 6 September 2026, comparing the requested path to the effective path on each and running a nonsense path against the host in the same run.
- Stored the one-month figures as price rows and recorded the seller's own Intro Pricing label inside every qualifier, so no comparison on this site can present them as standing rates.
- Derived the per-month equivalent of each three-month total and wrote the division into the qualifier rather than presenting a derived figure as published.
- Recorded the state footprint as a count and not as a list, because the pages read name no states.
- Screened the operating entity and the brand name against FDA's live warning-letter record with a known letter as a positive control and a nonsense string as a negative control in the same pass. Neither returned a letter. Untitled letters are published separately and were not searched.